There are several reasons the CTCA and cancer community at large are excited about the TAPUR trial’s possibilities:
It may lead to more treatment options. This trial aims to amass a broad pool of data that may help uncover new uses for existing drugs in more cancer types, based on specific abnormalities.
It’s truly precision medicine. Rather than targeting all cells in the body, hoping to impact the cancer cells most, precision medicine identifies the specific mutations that cause a specific type of cancer to develop. TAPUR is testing drugs that the FDA has concluded are safe and effective to treat specific mutations in specific cancer types. The TAPUR study aims to learn whether using these drugs in other cancer types with the same mutations will also yield safe and effective therapies. Therefore, TAPUR focuses on the mutations and is open to a wide range of cancer types.
It is more inclusive. Unlike studies with very rigid qualifications for eligibility, this trial is designed to include a wider patient population. As a result, TAPUR is learning from the experience of a wider array of cancer patients.
"This is the future of cancer research," says Dr. Markman. "It cannot be overstated how important this trial is. It changes the trajectory, the future, the thought processes for how oncologists treat cancer.”